Introduction {#sec1}
============

Substituted indoles play a pivotal role in drug discovery, culminating in launch of several drugs, and many molecules are in clinical pipeline.^[@ref1]−[@ref5]^ The discovery and development of drugs to treat allergic conditions and asthma has been of paramount importance in the pharmaceutical industry.^[@ref2]^ The success rate in this area of research has been significant because the human intralobar airways have a single receptor for peptido leukotrienes.^[@ref6]−[@ref8]^ There has been a great progress reported in identifying selective peptide leukotriene antagonists.^[@ref9]^ Indole and indazole compounds have been extensively studied as selective antagonists of the leukotriene pathway.^[@ref10]−[@ref13]^ These efforts have culminated in launching zafirlukast (**1**) as the oral leukotriene receptor antagonist for the maintenance treatment of asthma, prescribed in combination with bronchodilators and steroids.^[@ref14]−[@ref23]^ Other marketed products which have indole skeleton are panobinostat (**2**),^[@ref24]^ roxindole (**3**),^[@ref25],[@ref26]^ tropisetron (**4**),^[@ref27],[@ref28]^ etc ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).

![Representative drugs with 3-substituted indoles.](ao-2018-004769_0001){#fig1}

Zafirlukast attracted our attention owing to its biological profile along with our own interest to develop new strategies to build heterocyclic scaffolds for ongoing medicinal chemistry programmes.^[@ref29]−[@ref31]^ Traditionally, these classes of compounds are synthesized from prefabricated indole which offers lesser flexibility in substitutions in the benzene ring of indole.^[@ref1]^

Thus, a nonconventional strategy engaging indole construction as the key step of synthesis, unlike using substituted indoles as starting materials, was envisaged, thereby avoiding Fischer indole synthesis. In this regard, we aimed at the synthesis of 3-aroylindoles owing to easy manipulation of its carbonyl functionality. Few literature representative methods for the synthesis of 3-aroylindoles have been shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}.^[@ref32]−[@ref38]^ Recently, Patel et al. have reported an intramolecular copper-catalyzed sp^3^ C--H activation followed by C--C and C--O bond formation reactions to construct indole scaffold from alkynyl aniline.^[@ref36],[@ref37]^ Simultaneously, Liang and co-workers reported a palladium--copper-cocatalyzed 3-aroylindole synthesis.^[@ref38]^ We desired a peroxide-free and preferably transition metal-free cyclization protocol which prompted us to explore various oxidants to trigger the cyclization process of alkynyl *N*-methyl anilines to substituted indoles, which could in turn be transformed to zafirlukast.

![Representative Methods for 3-Aroylindoles](ao-2018-004769_0002){#sch1}

Initially, easily accessible *N*,*N*-dimethyl-2-(phenylethynyl)aniline **5a**([@ref39]) was subjected to sodium persulfate catalyzed oxidation to produce the indole **6a** in 75% yield. The optimum yields were obtained with three equivalents of sodium persulfate (see [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). After establishing the optimized conditions, we studied the scope and generality of the reaction with substituted *N*,*N*-dimethyl-2-(phenylethynyl)anilines **5** and obtained corresponding 3-aroylindoles (**6a--e**, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) in good yields (68--91%). In general, aryl rings substituted with electron-withdrawing groups gave higher yields (**6d**, 91% yield) compared to electron-donating groups. The procedure is also applicable to electron-rich aniline **5e** to give required product **6e** in 60% yield. The scalability of this reaction is proved by the preparation of 3-aroylindole **6d** in a large scale.

###### Optimization of Conditions for sp^3^ C--H Bond Activation[a](#t1fn1){ref-type="table-fn"}

![](ao-2018-004769_0006){#GRAPHIC-d35e338-autogenerated}

  entry   Na~2~S~2~O~8~ (equiv)   time (h)   yield[b](#t1fn2){ref-type="table-fn"}
  ------- ----------------------- ---------- ---------------------------------------
  1       0.1                     4          10
  2       0.2                     4          18
  3       0.3                     4          24
  4       0.4                     4          32
  5       0.5                     4          42
  6       1.0                     4          51
  7       2.0                     4          63
  8       2.5                     4          68
  9       3.0                     5          75
  10      4.0                     4          48

The reaction was carried out with **5a** (0.1 mmol) in DMSO (2 mL) under an inert atmosphere at 80 °C.

Yield of the isolated product **6a**.

###### Synthesis of Various 3-Aroylindoles[a](#t2fn1){ref-type="table-fn"}^,^[b](#t2fn2){ref-type="table-fn"}

![](ao-2018-004769_0007){#gr6}

The reaction was carried out with **5** (0.1 mmol) and Na~2~S~2~O~8~ (0.3 mmol) in DMSO (2 mL) under an inert atmosphere at 80 °C.

Yield of the isolated product **6**.

The synthesis of substituted indoles gave us the confidence to choose molecules containing indole skeleton and we narrowed down our search to zafirlukast. A retrosynthetic analysis of zafirlukast gave the key intermediate **6f**, which can be synthesized from the alkyne **5f** by extending our methodology. The alkyne can in turn be synthesized from 2-bromoaniline **7** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).

![Retrosynthetic Analysis of Zafirlukast](ao-2018-004769_0003){#sch2}

To add value to this reaction, appropriately substituted alkynyl aniline derivative **5f** was prepared in a one-pot three-step process. 2-bromoaniline **7** was subjected to Sonogashira coupling with trimethylsilyl-acetylene using palladium catalyst, followed by desilylation with the addition of K~2~CO~3~^[@ref40]^ and subsequent Sonogashira coupling in the same flask with methyl 4-iodo-3-methoxybenzoate **10** furnished **5f** in 58% overall yield over three steps ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). To our satisfaction, sodium persulfate in hot dimethyl sulfoxide (DMSO), in absence of any external catalyst, facilitated the entire sequence of sp^3^ C--H activation of N--Me group and formation of two new covalent C--C and C--O bonds in excellent yield (88%), to generate key intermediate **6f**.

![Synthesis of Zafirlukast](ao-2018-004769_0004){#sch3}

The task of converting **6f** to zafirlukast was accomplished following four easy synthetic transformations ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). Initially, **6f** was hydrogenated with Pd/C and H~2~ which under acidic workup provided the indole acid **8** in 76% yield.^[@ref41]^ The coupling of indole acid **8** with sulphonamide **11** in the presence of ZnCl~2~ catalyst afforded **9** in 92% yield.^[@ref42]^ The reduction of the nitro group in **9** was accomplished with Ra--Ni under a H~2~ atmosphere in EtOAc to yield 5-amino indole derivative in quantitative yield. This was converted to zafirlukast (**1**) by conjugating with cyclopentyl chloroformate **12** following reported procedure, using *N*-methyl morpholine, in excellent yield (89%).

On the basis of literature reports, a plausible mechanism has been proposed for this transformation ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). The aminyl radical cation **A** is formed by a single electron transfer process from the nitrogen atom of the *N*,*N*-dimethyl-2-(phenylethynyl)aniline (**5**). Abstraction of a hydrogen radical from N--Me gives an iminium intermediate **B**. The intramolecular cyclization of intermediate **B** via nucleophilic attack of the alkynyl group at the iminium carbon and subsequent addition of sodium persulfate gave enolate intermediate **C**. Then, ketonization of **C** afforded ketone **D**, which underwent further oxidation to provide 3-arolyindole **6**.

![Plausible Mechanism](ao-2018-004769_0005){#sch4}

In summary, an FDA-approved drug zafirlukast is synthesized in six steps starting from commercially available 2-bromo-*N*,*N*-dimethyl-4-nitroaniline engaging all catalytic transformations and almost with no protective groups. The key features are (i) one pot, three transformations to build biaryl alkynes, (ii) overall yield of 28%, and (iii) all the six steps requiring only 28 h overall for completing the process, which constitutes a very fast approach to the target.

General Details {#sec2}
===============

General Information {#sec2.1}
-------------------

All the reagents and solvents were of reagent grade and used without purification unless specified otherwise. All the dry reactions were performed under an atmosphere of nitrogen in flame-dried or oven-dried glassware with magnetic stirring. For reactions carried out using dry solvents, dimethylformamide (DMF), DMSO, CH~2~Cl~2~, were freshly distilled over calcium hydride and methanol was dried over calcium oxide. Technical grade ethyl acetate and hexane used for column chromatography were distilled prior to use. Column chromatography was carried out using silica gel (60--120 and 100--200 mesh) packed in glass columns. ^1^H and ^13^C NMR spectra were recorded at 400, 500 and 100, 125 MHz, respectively. Chemical shifts (δ) are reported in ppm, using the residual solvent peak in CDCl~3~ (H: δ = 7.26 and C: δ = 77.16 ppm) as the internal standard, and coupling constants (*J*) are given in Hz. High-resolution mass spectra (HRMS) were obtained by electron spray ionization (ESI) using an ESI-TOF mass spectrometer in positive ion mode (M + H or M + Na) as indicated.

Experimental Procedures and Analytical Data {#sec3}
===========================================

General Procedure for Intramolecular Oxidative Coupling via sp^3^ C--H Bond Activation (**6a--e**) {#sec3.1}
--------------------------------------------------------------------------------------------------

To a stirred solution of **5a--e** (0.1 mmol) in DMSO (3 mL), Na~2~S~2~O~8~ (0.3 mmol) was added into this mixture, and finally, the mixture was heated at 80 °C for 4 to 5 h. After completion of the reaction monitored by thin-layer chromatography (TLC), the reaction mixture was quenched with water (5 mL) and the product was extracted with ethyl acetate (2 × 5 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give 3-aroylindole products (**6a--e**).

### (1-Methyl-5-nitro-1*H*-indol-3-yl)(phenyl)methanone **6a** {#sec3.1.1}

By following the general procedure, compound **6a** was prepared (71 mg, 68%) as a yellow solid; *R*~f~ = 0.5 (silica, EtOAc/hexane = 1:9); mp = 134--136 °C; IR (neat): 3485, 2954, 2926, 2854, 1726, 1634, 1459, 1220, 894, 772, 688 cm^--1^; ^1^H NMR (400 MHz, CDCl~3~): δ 8.29 (d, *J* = 2.6 Hz, 1H), 8.15 (dd, *J* = 9.2, 2.6 Hz, 1H), 7.57--7.51 (m, 2H), 7.42--7.36 (m, 3H), 6.58 (d, *J* = 9.2 Hz, 1H), 5.47 (s, 1H), 3.05 (d, *J* = 5.2 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 158.0, 139.0, 131.5, 131.3, 129.0, 127.0, 125.2, 123.1, 115.0, 111.0, 95.5, 88.0, 43.0; HRMS (ESI-TOF) (*m*/*z*): calcd for \[M + H\]^+^ C~16~H~13~N~2~O~2~, 281.1690; found, 281.1702.

### (1-Methyl-5-nitro-1*H*-indol-3-yl)(*p*-tolyl)methanone **6b** {#sec3.1.2}

By following the general procedure, compound **6b** was prepared (75 mg, 71%) as a yellow solid; *R*~f~ = 0.6 (silica, EtOAc/hexane = 1:9); IR (neat): 2954, 2854, 2209, 1597, 1511, 1444, 1323, 1269, 1079, 906, 820, 772, 750 cm^--1^; mp = 113--118 °C; ^1^H NMR (500 MHz, CDCl~3~): δ 8.58 (d, *J* = 2.2 Hz, 1H), 8.15 (dd, *J* = 9.0, 2.2 Hz, 1H), 7.42--7.39 (m, 2H), 7.36 (d, *J* = 9.0 Hz, 1H), 7.32 (d, *J* = 7.8 Hz, 2H), 6.69 (d, *J* = 0.7 Hz, 1H), 3.79 (s, 3H), 2.45 (s, 3H); ^13^C NMR (125 MHz, CDCl~3~): δ 145.1, 142.0, 141.1, 139.0, 130.0, 129.4, 129.0, 127.3, 118.0, 117.3, 109.5, 104.0, 32.0, 21.5; HRMS (ESI-TOF) (*m*/*z*): calcd for \[M + H\]^+^ C~17~H~15~N~2~O~3~, 295.1083; found, 295.1084.

### (4-Methoxyphenyl)(1-methyl-5-nitro-1*H*-indol-3-yl)methanone **6c** {#sec3.1.3}

By following the general procedure, compound **6c** was prepared (77 mg, 73%) as a yellow solid; *R*~f~ = 0.5 (silica, EtOAc/hexane = 3:7); mp = 142--144 °C; IR (neat): 3415, 2928, 2838, 1738, 1627, 1534, 1416, 1318, 1219, 894, 772, 685 cm^--1^; ^1^H NMR (400 MHz, CDCl~3~): δ 9.25 (d, *J* = 1.9 Hz, 1H), 8.22 (dd, *J* = 9.0, 1.5 Hz, 1H), 7.85 (t, *J* = 5.5 Hz, 2H), 7.69 (s, 1H), 7.41 (d, *J* = 9.0 Hz, 1H), 7.02--6.98 (m, 2H), 3.93 (s, 3H), 3.90 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 189.0, 163.0, 144.0, 140.2, 139.1, 132.5, 131.1, 121.0, 120.0, 119.1, 117.5, 114.0, 110.0, 57.0, 34.1; HRMS (ESI-TOF) (*m*/*z*): calcd for \[M + H\]^+^ C~17~H~15~N~2~O~4~^+^, 311.1032; found, 311.1039.

### (1-Methyl-5-nitro-1*H*-indol-3-yl)(2-nitrophenyl)methanone **6d** {#sec3.1.4}

By following the general procedure, compound **6d** was prepared (95 mg, 91%) as a yellow solid; *R*~f~ 0.6 (silica, EtOAc/hexane = 2:8); mp = 188--190 °C; IR (neat): 3423, 3098, 2946, 1740, 1614, 1577, 1524, 1326, 1142, 1068, 855, 756, 670 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 8.58 (d, *J* = 2.2 Hz, 1H), 8.19--8.14 (m, 2H), 7.77 (td, *J* = 7.5, 1.3 Hz, 1H), 7.70 (td, *J* = 7.9, 1.5 Hz, 1H), 7.56 (dd, *J* = 7.5, 1.5 Hz, 1H), 7.38 (d, *J* = 9.1 Hz, 1H), 6.66 (d, *J* = 0.6 Hz, 1H), 3.60 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 149.5, 142.1, 140.4, 139.4, 134.0, 133.3, 131.0, 127.0, 125.0, 118.1, 118.0, 110.0, 105.0, 31.2; HRMS (ESI-TOF) (*m*/*z*): calcd for \[M + H\]^+^ C~16~H~11~N~3~O~5~, 326.1489; found, 598.1474.

### (1-Methyl-1*H*-indol-3-yl)(phenyl)methanone **6e** {#sec3.1.5}

By following the general procedure, compound **6e** was prepared (64 mg, 60%) as a viscous liquid; *R*~f~ 0.7 (silica, EtOAc/hexane = 1:19); IR (neat): 3479, 3392, 2926, 2856, 1642, 1523, 1459, 1220, 1065, 772, 695 cm^--1^; ^1^H NMR (400 MHz, CDCl~3~): δ 8.46--8.40 (m, 1H), 7.81--7.76 (m, 2H), 7.54--7.49 (m, 1H), 7.49--7.42 (m, 3H), 7.32 (dd, *J* = 5.7, 3.6 Hz, 3H), 3.78 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 190.9, 140.9, 138.1, 137.6, 131.1, 128.7, 128.3, 123.7, 122.7, 122.7, 115.5, 109.7, 33.6; HRMS (ESI-TOF) (*m*/*z*): calcd for \[M + H\]^+^ C~16~H~14~NO, 236.1075; found, 236.1063.

Experimental Procedures for the Total Synthesis of Zafirlukast {#sec3.2}
--------------------------------------------------------------

### One-Pot Synthesis of Intermediate **5f** {#sec3.2.1}

To a mixture of aryl bromide **7** (5.0 g, 20.41 mmol), PdCl~2~ (PPh~3~)~2~ (143 mg, 10 mol %), CuI (39 mg, 10 mol %) and Et~3~N (4.3 mL, 30.61 mmol) was added in dry DMF (80 mL); then, trimethylsilyl acetylene (5.5 mL, 20.41 mmol) was added slowly at room temperature, and the resultant mixture was stirred for 2 h at 80 °C. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, and then, K~2~CO~3~ (3.9 g, 30.61 mmol) was added to this mixture then heating was continued until the silylated acetylene disappeared (monitored by TLC). Once again, the reaction was allowed to come to room temperature, then added with PdCl~2~ (PPh~3~)~2~ (143 mg, 10 mol %), Et~3~N (4.3 mL, 30.61 mmol), and CuI (39 mg, 10 mol %), and continued stirring for 30 min at room temperature. Finally, aryl iodide **10** (5.9 g, 20.41 mmol) in DMF (10 mL) was added dropwise in residual mixture, and then resultant mixture was heated for 3 h at 80 °C. The reaction mixture was re-cooled to room temperature and quenched with cold water (70 mL), and the solid was filtered using with EtOAc (150 mL). Then, the organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to provide the biaryl acetylene **5f** (3.9 g, 58% in 3 steps) as a yellow solid; *R*~f~ = 0.7 (silica, EtOAc/hexane = 3:7); mp = 152--154 °C; IR (neat): 3476, 3226, 2951, 2925, 2850, 1723, 1622, 1582, 1435, 1293, 1108, 767 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 8.38 (d, *J* = 2.8 Hz, 1H), 8.05 (dd, *J* = 9.3, 2.8 Hz, 1H), 7.64 (dd, *J* = 7.9, 1.3 Hz, 1H), 7.57 (d, *J* = 1.0 Hz, 1H), 7.51 (d, *J* = 7.9 Hz, 1H), 6.76 (d, *J* = 9.4 Hz, 1H), 3.96 (s, 3H), 3.94 (s, 3H), 3.29 (s, 6H); ^13^C NMR (125 MHz, CDCl~3~): δ 167.0, 160.1, 157.4, 138.5, 133.0, 132.0, 131.2, 125.5, 122.0, 117.2, 115.0, 111.4, 110.1, 94.5, 91.3, 56.1, 52.5, 43.0; HRMS (ESI-TOF) (*m*/*z*): calcd for \[M + H\]^+^ C~19~H~19~N~2~O~5~, 355.1294; found, 355.1299.

### Methyl 3-Methoxy-4-(1-methyl-5-nitro-1*H*-indole-3-carbonyl) Benzoate **6f** {#sec3.2.2}

To a stirred solution of methyl 4-((2-(dimethyl amino)-5-nitrophenyl)ethynyl)-3-methoxybenzoate **5f** (3.0 g, 8.47 mmol) in dry DMSO (50 mL), was added Na~2~S~2~O~8~ (6.05 g, 25.42 mmol). The resultant mixture was heated to 80 °C for 5 h. The resultant reaction mixture was quenched with water (60 mL) and extracted with ethyl acetate (2 × 50 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give methyl 3-methoxy-4-(1-methyl-5-nitro-1*H*-indole-3-carbonyl) benzoate **6f** (2.75 g, 88%) as a yellow solid; *R*~f~ = 0.5 (silica, EtOAc/hexane = 4:6); mp = 198--200 °C; IR (neat): 2924, 2854, 1724, 1634, 1527, 1464, 1371, 1293, 1232, 1142, 1026, 952, 770 cm^--1^; ^1^H NMR (400 MHz, CDCl~3~): δ 9.29 (d, *J* = 2.2 Hz, 1H), 8.23 (dd, *J* = 9.0, 2.3 Hz, 1H), 7.73 (dd, *J* = 7.7, 1.4 Hz, 1H), 7.69 (d, *J* = 1.2 Hz, 1H), 7.45 (d, *J* = 5.6 Hz, 1H), 7.42 (d, *J* = 1.0 Hz, 1H), 7.38 (d, *J* = 17.6 Hz, 1H), 3.97 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 189.0, 166.5, 157.0, 144.3, 141.0, 140.4, 134.3, 133.0, 129.0, 126.0, 122.0, 120.0, 119.4, 118.5, 113.0, 110.1, 56.2, 53.0, 34.2; HRMS (ESI-TOF) (*m*/*z*): calcd for \[M + H\]^+^ C~19~H~17~N~2~O~6~, 369.1087; found, 369.1085.

### 3-Methoxy-4-(1-methyl-5-nitro-1*H*-indole-3-carbonyl) Benzoic Acid **8** {#sec3.2.3}

To a stirred solution of compound **6f** (2.0 g, 5.43 mmol) in MeOH (20 mL), were added 5% Pd--C (0.2 g, 5 mol %) and concd HCl (0.2 equiv) sequentially. The flask was evacuated and pressurized with H~2~ (balloon) atmosphere, and the reaction mixture was stirred for 6 h. After completion of the reaction, the solvent was removed under reduced pressure, and the pH value of the reaction mixture was adjusted to 2 with aq HCl (2.0 M) and stirred at room temperature for 3 h. The reaction mixture was filtered using diethyl ether and dried over anhydrous sodium sulfate. The organic layer was concentrated under reduced pressure and purified by column chromatography to give compound **8** (1.4 g, 76%) as a yellow solid; *R*~f~ = 0.5 (silica, EtOAc/hexane = 7:3); mp = 183--185 °C; IR (neat): 3417, 2951, 2852, 1725, 1622, 1661, 1583, 1435, 1293, 1047, 995, 825, 769 cm^--1^; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 8.51 (d, *J* = 2.2 Hz, 1H), 8.02 (dd, *J* = 9.1, 2.3 Hz, 1H), 7.59 (d, *J* = 9.1 Hz, 1H), 7.50--7.45 (m, 2H), 7.36 (s, 1H), 7.25 (d, *J* = 7.8 Hz, 1H), 4.11 (s, 2H), 3.91 (s, 3H), 3.81 (s, 3H); ^13^C NMR (100 MHz, DMSO-*d*~6~): δ 167.2, 157.0, 140.3, 139.4, 134.1, 132.0, 130.1, 130.0, 126.5, 122.0, 116.4, 116.0, 115.3, 111.0, 110.3, 55.5, 33.0, 24.4; HRMS (ESI-TOF) (*m*/*z*): calcd for \[M + H\]^−^ calcd for C~18~H~15~N~2~O~5~, 339.0981; found, 339.0967.

### 3-Methoxy-4-(1-methyl-5-nitro-1*H*-indole-3-carbonyl)-*N*-(*o*-tolylsulfonyl) Benzamide **9** {#sec3.2.4}

To a stirred solution of anhydrous ZnCl~2~ (2 mg, 30 mol %) in anhydrous dichloromethane (DCM; 2 mL), acid **8** (300 mg, 0.88 mmol) was added followed by the addition of benzoic anhydride (0.12 mL, 1.05 mmol) under a nitrogen atmosphere at room temperature. After 10 min, a solution of sulphonamide **11** (16 mg, 0.88 mmol) in DCM (1 mL) was added dropwise, and the resulting reaction mixture was stirred at room temperature for 2 h. After completion of the reaction, the reaction mixture was quenched with water (5 mL), and the mixture was extracted with DCM (2 × 10 mL); then, the organic layer was washed with brine, and the combined organic layer were dried over sodium sulfate and evaporated under reduced pressure. The crude compound was purified by column chromatography to afford title product **9** (406 mg, 92%) as a yellow solid; *R*~f~ = 0.5 (silica, EtOAc/hexane = 8:2); mp = 152--154 °C; IR (neat): 3479, 2925, 2850, 1723, 1622, 1582, 1435, 1293, 1108, 767, 671 cm^--1^; ^1^H NMR (400 MHz, CDCl~3~): δ 9.43 (s, 1H), 8.51 (d, *J* = 2.2 Hz, 1H), 8.25 (dd, *J* = 8.0, 1.1 Hz, 1H), 8.10 (dd, *J* = 9.1, 2.2 Hz, 1H), 7.52 (td, *J* = 7.5, 1.2 Hz, 1H), 7.40 (dd, *J* = 13.9, 5.9 Hz, 2H), 7.31--7.26 (m, 3H), 7.14 (d, *J* = 7.8 Hz, 1H), 6.92 (s, 1H), 4.10 (s, 2H), 3.88 (s, 3H), 3.78 (s, 3H), 2.68 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 164.2, 157.7, 141.4, 140.0, 138.0, 137.0, 136.0, 134.2, 133.0, 132.0, 130.5, 130.4, 130.1, 127.2, 127.0, 120.0, 117.5, 117.0, 116.0, 110.1, 109.3, 56; HRMS (ESI-TOF) (*m*/*z*): calcd for \[M + Na\]^+^ C~25~H~23~N~3~O~6~SNa, 516.1988; found, 516.1975.

### Cyclopentyl(3-(2-methoxy-4-((*o*-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1*H*-indol-5-yl)carbamate (**1**) {#sec3.2.5}

A solution of *N*-{3-methyl-4-(*N*-methyl-5-nitro-1*H*-3-indolyl)methyl benzoyl}-2-methyl-1-benzenesulfonamide **9** (100 mg, 0.20 mmol) in MeOH (2 mL) and Ra--Ni (2 mg, 5 mol %) was placed under hydrogen balloon pressure at room temperature for 2 h. The reaction mass was filtered through a celite bed, and the catalyst was washed with diethyl ether (2 × 10 mL); the combined filtrates were concentrated under reduced pressure and dried using high vacuum for 1 h. The obtained residue and *N*-methyl morphine (26 μL, 0.24 mmol) were dissolved in DCM (2 mL), and then, cyclopentyl chloroformate was added slowly (25 μL, 0.20 mmol) in 0 °C. The resulting reaction mixture was stirred at room temperature for 3 h. After completion of the reaction, the solvent was evaporated under reduced pressure, and the solid precipitate was washed with water (5 mL) and then extracted with DCM (10 mL) and dried over sodium sulfate and evaporated in under reduced pressure. The crude compound was purified by column chromatography to afford title product **1** (102 mg, 89%) as a white solid; *R*~f~ = 0.7 (silica, EtOAc/hexane = 4:6); mp = 137--141 °C; IR (neat): 3476, 2951, 2925, 2850, 1723, 1689, 1554, 1499, 1431, 1270, 1163, 1062, 1036, 872, 758 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 9.18 (s, 1H), 8.26 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.51 (td, *J* = 7.5, 1.3 Hz, 2H), 7.40 (t, *J* = 7.5 Hz, 1H), 7.31 (d, *J* = 1.5 Hz, 1H), 7.29 (d, *J* = 7.5 Hz, 1H), 7.19 (d, *J* = 8.6 Hz, 1H), 7.16 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.09 (d, *J* = 7.9 Hz, 2H), 6.77 (s, 1H), 6.51 (s, 1H), 5.18 (ddd, *J* = 8.9, 5.9, 2.6 Hz, 1H), 4.03 (s, 2H), 3.85 (s, 3H), 3.70 (s, 3H), 2.68 (s, 3H), 1.86 (s, 2H), 1.74 (d, *J* = 12.6 Hz, 4H), 1.60 (s, 2H); ^13^C NMR (125 MHz, CDCl~3~): δ 164.4, 158.0, 138.0, 137.0, 137.0, 134.4, 134.1, 133.0, 138.0, 130.1, 130.0, 128.4, 128.1, 127.0, 119.4, 115.2, 112.0, 110.0, 110.0, 56.0, 33.0, 33.0, 25.4, 24.0, 21.0; HRMS (ESI-TOF) (*m*/*z*): calcd for \[M + Na\]^+^ C~31~H~33~N~3~O~6~SNa, 598.1988; found, 598.1975.
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